MCID: HMG002
MIFTS: 50

Hemoglobinuria

Categories: Blood diseases, Immune diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to paroxysmal nocturnal hemoglobinuria 1 and blackwater fever, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Cell surface interactions at the vascular wall. The drugs Ravulizumab and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hemoglobinuria is a condition in which the oxygen transport protein hemoglobin is found in abnormally... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 421)
# Related Disease Score Top Affiliating Genes
1 paroxysmal nocturnal hemoglobinuria 1 35.0 PIGT PIGA
2 blackwater fever 32.5 MB HP G6PD
3 aplastic anemia 32.3 THBD SERPINC1 PIGA CSF3 CD59 CD55
4 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 31.4 HP G6PD CSF3
5 thrombophilia due to thrombin defect 31.4 THBD SERPINC1 F2
6 budd-chiari syndrome 31.2 SERPINC1 F2 CD59
7 acute kidney failure 31.1 MB HP F2
8 thrombosis 31.0 THBD SERPINC1 F2 CD55
9 paroxysmal nocturnal hemoglobinuria 30.9 THBD SERPINC1 PLAUR PIGT PIGH PIGA
10 retinitis pigmentosa and erythrocytic microcytosis 30.9 PIGA CSF3
11 deficiency anemia 30.9 SERPINC1 MB HP G6PD
12 myelodysplastic syndrome 30.9 PIGA CSF3 CR1 CD59 CD55
13 multiple congenital anomalies-hypotonia-seizures syndrome 2 30.6 PIGT PIGA CD59 CD55
14 purpura 30.6 THBD SERPINC1 F2 C3
15 anemia, autoimmune hemolytic 30.6 HP G6PD CD59 CD55 C3
16 hypersplenism 30.5 SERPINC1 F2 CSF3
17 severe pre-eclampsia 30.4 SERPINC1 C5 C3
18 splenic infarction 30.2 SERPINC1 HP F2
19 sagittal sinus thrombosis 30.2 SERPINC1 F2
20 branch retinal artery occlusion 30.2 SERPINC1 F2
21 bilirubin metabolic disorder 30.1 HP G6PD F2
22 leukemia, chronic lymphocytic 30.1 FCGR3B CSF3 CR1 CD59 CD58 CD55
23 aseptic meningitis 30.1 CSF3 CFI CD58
24 disseminated intravascular coagulation 30.1 THBD SERPINC1 MB F2
25 varicose veins 30.1 THBD SERPINC1 F2
26 splenic sequestration 30.0 HP F2
27 pulmonary embolism 30.0 THBD SERPINC1 MB F2
28 thrombocytopenia 30.0 THBD SERPINC1 HP F2 CSF3 CFI
29 anuria 30.0 MB HP F2
30 antiphospholipid syndrome 29.9 THBD SERPINC1 F2 C3
31 essential thrombocythemia 29.9 THBD SERPINC1 F2 CSF3
32 intracranial embolism 29.9 SERPINC1 F2
33 genetic atypical hemolytic-uremic syndrome 29.9 THBD CFI C3
34 enterocolitis 29.9 THBD CFI C3
35 thrombocytosis 29.9 SERPINC1 F2 CSF3
36 homocysteinemia 29.8 THBD SERPINC1 F2
37 sickle cell anemia 29.8 G6PD F2 CSF3
38 hepatic coma 29.8 SERPINC1 F2
39 central retinal artery occlusion 29.7 SERPINC1 F2
40 pneumonia 29.7 MB F2 CSF3 CR1
41 diarrhea 29.7 THBD CSF3 CFI CD55 C3
42 glomerulonephritis 29.7 CR1 CFI CD55 C3
43 central retinal vein occlusion 29.6 SERPINC1 G6PD F2
44 thrombotic thrombocytopenic purpura 29.6 THBD SERPINC1 HP CFI C3
45 peripheral vascular disease 29.6 THBD SERPINC1 F2
46 hemolytic anemia 29.6 THBD PIGA HP G6PD F2 CSF3
47 hemolytic-uremic syndrome 29.2 THBD SERPINC1 HP F2 CFI CD55
48 stroke, ischemic 29.2 THBD SERPINC1 MB F2
49 hemolytic uremic syndrome, atypical 1 29.1 THBD PIGA HP CR1 CFI CD59
50 myocardial infarction 29.0 THBD SERPINC1 MB HP F2 CSF3

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria, other and unspecified genitourinary symptoms

GenomeRNAi Phenotypes related to Hemoglobinuria according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.5 PLAUR
2 Decreased viability GR00221-A-1 9.5 PLAUR
3 Decreased viability GR00221-A-2 9.5 PLAUR
4 Decreased viability GR00221-A-4 9.5 PLAUR
5 Decreased viability GR00240-S-1 9.5 CD59
6 Decreased viability GR00249-S 9.5 C5 G6PD HP PIGA
7 Decreased viability GR00386-A-1 9.5 C3 C5 CSF3 G6PD MB
8 Decreased viability GR00402-S-2 9.5 G6PD

MGI Mouse Phenotypes related to Hemoglobinuria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 C3 CD55 CD59 CFI CSF3 F2
2 homeostasis/metabolism MP:0005376 10.1 C3 C5 CD55 CD59 CFI F2
3 immune system MP:0005387 9.9 C3 C5 CD55 CSF3 F2 FCGR3B
4 mortality/aging MP:0010768 9.77 C3 C5 CD55 CD59 F2 G6PD
5 renal/urinary system MP:0005367 9.28 C3 CD55 CD59 CFI CSF3 HP

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
2
Warfarin Approved Phase 4 81-81-2 6691 54678486
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
6 Pharmaceutical Solutions Phase 4
7 Antibodies, Monoclonal Phase 4
8 Rho(D) Immune Globulin Phase 4
9 Immunoglobulins, Intravenous Phase 4
10 gamma-Globulins Phase 4
11 Thymoglobulin Phase 4
12 Complement C3 Phase 4
13 Complement C3d Phase 4
14 Anti-Bacterial Agents Phase 4
15 Anticoagulants Phase 4
16 Antibiotics, Antitubercular Phase 4
17
Iodine Approved, Investigational Phase 3 7553-56-2 807
18
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
19
Protein C Approved Phase 3
20 Antilymphocyte Serum Phase 3
21 Muromonab-CD3 Phase 3
22
Lenograstim Approved, Investigational Phase 2 135968-09-1
23
Basiliximab Approved, Investigational Phase 2 152923-56-3, 179045-86-4
24
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
25
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
26
Etoposide Approved Phase 2 33419-42-0 36462
27
Melphalan Approved Phase 2 148-82-3 460612 4053
28
Busulfan Approved, Investigational Phase 2 55-98-1 2478
29
Mycophenolic acid Approved Phase 2 24280-93-1 446541
30
leucovorin Approved Phase 2 58-05-9 6006 143
31
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
32
Mesna Approved, Investigational Phase 2 3375-50-6 598
33
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
34
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
35
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
36
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
37
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492 6473866
38
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
39
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
40 glucocorticoids Phase 2
41 Anthelmintics Phase 2
42 Hormone Antagonists Phase 2
43 Antiparasitic Agents Phase 2
44 Alkylating Agents Phase 2
45 Etoposide phosphate Phase 2
46 Antimetabolites Phase 2
47 Antitubercular Agents Phase 2
48 Vitamin B Complex Phase 2
49 Folic Acid Antagonists Phase 2
50 Folate Phase 2

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria Completed NCT00867932 Phase 4 Eculizumab
2 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
3 The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial] Active, not recruiting NCT02013037 Phase 4 Eculizumab
4 Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Not yet recruiting NCT04320602 Phase 4
5 Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory Classic Paroxysmal Nocturnal Hemoglobinuria ,a Prospective Study Not yet recruiting NCT03866681 Phase 4 sirolimus
6 Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation Unknown status NCT02498340 Phase 2, Phase 3
7 Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH Completed NCT00122317 Phase 3 eculizumab
8 Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients Completed NCT00122330 Phase 3 eculizumab
9 Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study Completed NCT00122304 Phase 3 eculizumab
10 A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00098280 Phase 3 Eculizumab
11 TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00112983 Phase 3
12 SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design Completed NCT00130000 Phase 3 Eculizumab
13 Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
14 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
15 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
16 A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT04085601 Phase 3 APL-2
17 A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03818607 Phase 3 ABP 959;Eculizumab
18 A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03406507 Phase 3
19 CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study Recruiting NCT03829449 Phase 3 rVA576 (Coversin)
20 Randomized, Open-Label, International, Multi-center, Comparative Study of Efficacy and Safety of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Patients With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT04060264 Phase 3
21 Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Recruiting NCT03588026 Phase 3 rVA576
22 A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB12 (Proposed Eculizumab Biosimilar) and Soliris® in Subjects With Paroxysmal Nocturnal Haemoglobinuria Recruiting NCT04058158 Phase 3 SB12 (proposed eculizumab biosimilar);Soliris (eculizumab)
23 A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT03500549 Phase 3 APL-2;Soliris
24 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
25 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Active, not recruiting NCT03056040 Phase 3
26 An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria Enrolling by invitation NCT04162470 Phase 3 REGN3918
27 An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) Enrolling by invitation NCT03531255 Phase 3 APL-2
28 A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. Not yet recruiting NCT04434092 Phase 3 Crovalimab;Eculizumab
29 A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. Not yet recruiting NCT04432584 Phase 3 Crovalimab;Eculizumab
30 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
31 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
32 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2 Eculizumab
33 Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients Unknown status NCT00895739 Phase 2 cyclosporine
34 Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol Completed NCT01194804 Phase 2 Eculizumab
35 Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT01192399 Phase 2
36 A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT03053102 Phase 2 ACH-0144471
37 A Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have an Inadequate Response to Eculizumab Completed NCT03030183 Phase 2 Zilucoplan (RA101495)
38 A Phase 1/2 Single-ascending and Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-CC5 in Healthy Adult Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT02352493 Phase 1, Phase 2 ALN-CC5;Sterile Normal Saline (0.9% NaCl)
39 High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Completed NCT00004464 Phase 2 cyclophosphamide;filgrastim
40 Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Completed NCT03078582 Phase 2 Zilucoplan (RA101495)
41 Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH). Completed NCT03593200 Phase 2 APL-2
42 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Completed NCT02591862 Phase 2 Coversin
43 A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
44 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2 Basiliximab
45 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
46 Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (>18 Years) With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
47 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
48 Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial Completed NCT00397813 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
49 Haploidentical Stem Cell Transplantation Utilizing T-Cell Depletion as Therapy for Patients With Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
50 A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

# Genetic test Affiliating Genes
1 Hemoglobinuria 29

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

40
Bone, Bone Marrow, Kidney, Testes, T Cells, Neutrophil, Monocytes

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 3400)
# Title Authors PMID Year
1
The prevalence of G6PD deficiency in blood transfusion recipients. 61 54
17364999 2007
2
[Post-hemolytic renal failure in children with glucose-6-phosphate dehydrogenase deficiency at the University Hospital Center in Lome]. 54 61
12910652 2003
3
Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. 54 61
11340138 2001
4
Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. 54 61
11372733 2001
5
Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease. 54 61
10539884 1999
6
Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. 61 54
9844822 1998
7
Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. 54 61
8953071 1996
8
Serum transcobalamin II level in glucose-6-phosphate dehydrogenase deficient subjects with typhoid fever. 61 54
8708525 1996
9
Persistently elevated serum transcobalamin II in a patient with cerebral malaria and typhus infections. 61 54
7622977 1995
10
Repeated large-dose haptoglobin therapy in an extensively burned patient: case report. 54 61
8163802 1994
11
Hemolytic effect of the Amplatz thrombectomy device. 61 54
8136596 1994
12
[Intensive care of a postpartum patient complicated with HELLP syndrome]. 61 54
8320814 1993
13
Regulation of renal function in thermal injury. 61 54
2147724 1990
14
[Administration of haptoglobin in ABO incompatible bone marrow transplantation]. 54 61
2255063 1990
15
Polyethylene Oxide (PEO) molecular size determines the severity of atypical thrombotic microangiopathy in a guinea pig model of acute intravenous exposure. 61
32579216 2020
16
Acute kidney injury following percutaneous mechanical thrombectomy of subclavian artery stent graft thrombosis: a case report. 61
32476066 2020
17
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. 61
32519233 2020
18
Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. 61
32073845 2020
19
Blood Cell Disorders and the Nervous System. 61
32487901 2020
20
Battle of the clones: paroxysmal nocturnal hemoglobinuria vs myelodysplastic syndrome. 61
32533252 2020
21
Pediatric Paroxysmal Nocturnal Hemoglobinuria Presenting as Acute Kidney Injury. 61
32496445 2020
22
Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab. 61
32542443 2020
23
Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment. 61
32202389 2020
24
Presence of paroxysmal nocturnal hemoglobinuria in patients with idiopathic portal vein thrombosis: a single-center study. 61
32490645 2020
25
Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria - multicenter analysis by Polish Adult Leukemia Group. 61
32512214 2020
26
Acute hemolytic reaction due to A-B mismatched transfusion in a cat with transient AB blood type. 61
32141165 2020
27
Acute fulminant hemolysis after transcatheter mitral valve replacement for mitral annular calcification. 61
32374902 2020
28
Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. 61
32390114 2020
29
Screening for paroxysmal nocturnal hemoglobinuria (PNH) in patients presenting with cerebral sinovenous thrombosis (CSVT): Results of a FLAER based flowcytometry study in Indian patients. 61
31701360 2020
30
[Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab]. 61
30848313 2020
31
Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes. 61
32396613 2020
32
FLAER-negative CD15+ neutrophils can be used for the simplified screening of suspected PNH cases. 61
32449605 2020
33
Complementopathies and precision medicine. 61
32310222 2020
34
Expansion of paroxysmal nocturnal hemoglobinuria clones in MPLW515L mutation harboring primary myelofibrosis. 61
32444893 2020
35
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. 61
31885297 2020
36
Pregnancy-associated immune-mediated hemolytic anemia in a dog. 61
32189467 2020
37
Roles of immune responses in the pathogenesis of immunorelated pancytopenia. 61
32474938 2020
38
Cryptogenic cerebral venous thrombosis in a multiple-sclerosis-patient treated with Alemtuzumab. 61
32540745 2020
39
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. 61
32430502 2020
40
Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. 61
31582549 2020
41
Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry. 61
32195308 2020
42
Identification of acquired PIGA mutations and additional variants by next-generation sequencing in paroxysmal nocturnal hemoglobinuria. 61
32359022 2020
43
The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis. 61
32101880 2020
44
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. 61
32311169 2020
45
Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting. 61
30912620 2020
46
Tangential flow filtration of haptoglobin. 61
32348635 2020
47
Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Clones: Time for a Change. 61
32309782 2020
48
Risk factors associated with poor response to immunosuppressive therapy in acquired aplastic anemia: A meta-analysis of retrospective studies. 61
32256799 2020
49
A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. 61
32338085 2020
50
A rare case report of autoimmune haemolytic anemia in a female child due to a Donath-Landsteiner antibody. 61
32249165 2020

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 PLAUR HP FCGR3B CSF3 CR1 CFI
2
Show member pathways
12.01 THBD F2 CEACAM8 CD58
3
Show member pathways
11.83 CR1 CFI CD59 CD55 C5 C3
4 11.75 CSF3 CEACAM8 CD59
5 11.66 CSF3 CR1 CD59 CD55
6
Show member pathways
11.65 PLAUR PIGT PIGH PIGA FCGR3B
7 11.6 FCGR3B CR1 C3
8 11.6 FCGR3B CFI C5 C3
9
Show member pathways
11.59 CR1 CFI CD59 CD55 C5 C3
10
Show member pathways
11.56 CD55 C5 C3
11 11.48 THBD SERPINC1 PLAUR F2 CR1 CFI
12
Show member pathways
11.19 PIGT PIGH PIGA

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 SERPINC1 PLAUR HP FCGR3B F2 CSF3
2 extracellular space GO:0005615 9.96 THBD SERPINC1 HP F2 CSF3 CFI
3 endoplasmic reticulum lumen GO:0005788 9.8 SERPINC1 PLAUR F2 C3
4 blood microparticle GO:0072562 9.71 SERPINC1 HP F2 C3
5 secretory granule membrane GO:0030667 9.67 FCGR3B CR1 CD58 CD55
6 specific granule membrane GO:0035579 9.65 PLAUR CEACAM8 CD59
7 ficolin-1-rich granule membrane GO:0101003 9.61 CR1 CD58 CD55
8 cell surface GO:0009986 9.56 THBD PLAUR CR1 CEACAM8 CD59 CD58
9 anchored component of membrane GO:0031225 9.55 PLAUR FCGR3B CEACAM8 CD59 CD55
10 extracellular exosome GO:0070062 9.47 SERPINC1 MB HP G6PD FCGR3B F2
11 glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex GO:0000506 9.46 PIGH PIGA

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.95 CR1 CFI CD55 C5 C3
2 immune system process GO:0002376 9.93 HP CR1 CFI CD55 C5 C3
3 cell surface receptor signaling pathway GO:0007166 9.86 FCGR3B F2 CD59 C5
4 leukocyte migration GO:0050900 9.73 THBD F2 CEACAM8 CD58
5 blood coagulation GO:0007596 9.65 THBD SERPINC1 PLAUR F2 CD59
6 neutrophil degranulation GO:0043312 9.61 PLAUR HP FCGR3B CR1 CEACAM8 CD59
7 fibrinolysis GO:0042730 9.57 PLAUR F2
8 complement activation, classical pathway GO:0006958 9.55 CR1 CFI CD55 C5 C3
9 preassembly of GPI anchor in ER membrane GO:0016254 9.54 PIGH PIGA
10 hemostasis GO:0007599 9.54 THBD SERPINC1 F2
11 regulation of blood coagulation GO:0030193 9.52 SERPINC1 F2
12 complement activation, alternative pathway GO:0006957 9.51 C5 C3
13 GPI anchor biosynthetic process GO:0006506 9.5 PIGT PIGH PIGA
14 negative regulation of fibrinolysis GO:0051918 9.49 THBD F2
15 negative regulation of platelet activation GO:0010544 9.48 THBD F2
16 regulation of complement-dependent cytotoxicity GO:1903659 9.4 CD59 CD55
17 regulation of complement activation GO:0030449 9.17 F2 CR1 CFI CD59 CD55 C5

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.35 PLAUR F2 CD58 C5 C3
2 phosphatidylinositol N-acetylglucosaminyltransferase activity GO:0017176 8.62 PIGH PIGA

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....